Gilead Sciences (GILD) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a manageable bar after Q1 beat-and-raise, but the stock has given back all post-Q1 gains, suggesting the market wants proof that Yeztugo momentum is durable and that the underlying business can absorb the IPR&D drag.

Heading into Q2 2026, the bar for Gilead is achievable but not low. Management raised full-year product sales guidance by $400 million after Q1 (to $30.0–$30.4 billion), and consensus has largely tracked that raise, leaving little room for a second upside surprise unless Yeztugo meaningfully outperforms the ~$227 million Q2 estimate. Guidance tone remains confident — management has explicitly committed to top-quartile operating margins and characterized the three recent acquisitions (Arcellx, Tubulis, Ouro) as manageable within existing opex envelopes — but the stock has drifted ~2% below its May 7 earnings-day close, underperforming XLV by roughly 15 percentage points since last print, suggesting sentiment is cautious rather than stretched. The primary wildcard is the BIC/LEN PDUFA date of August 27, 2026: any FDA communication ahead of earnings — positive or negative — could materially shift the narrative, as BIC/LEN is positioned as the next major HIV franchise driver with a targeted late-August launch and meaningful 2027 ramp. On the downside, the California Supreme Court ruling on August 3 (rejecting negligence claims related to HIV drug development) removes a tail risk but is unlikely to be a positive catalyst on its own.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar on revenue and Biktarvy, but Yeztugo is the swing factor — any print above ~$250M would likely be read as a meaningful beat given the trajectory from $166M in Q1.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of August 3, 2026. Non-GAAP EPS for Q2 2026 is heavily distorted by acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines; underlying operating EPS (ex-IPR&D) is the more relevant metric for the quarter. FY 2026 guidance per Q1 2026 earnings release (May 7, 2026).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Biktarvy & Yeztugo)

Pattern: Biktarvy has beaten consensus in 6 of the last 7 reported quarters, with the sole miss in Q1 2025 driven by inventory dynamics. Yeztugo is still in early launch ramp — the Q4 2025 miss was the only meaningful shortfall, and Q1 2026 returned to beat territory. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised at Q1 2026 earnings (May 7) and has not been formally revised since; tone remains confident on HIV and Yeztugo, with management absorbing acquisition costs within existing opex guidance.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have tracked guidance closely since the Q1 raise, with Yeztugo consensus slightly above management’s ~$1.0B FY target — a modest cushion that could flip to risk if Q2 sequential growth disappoints.

Source: Visible Alpha Consensus and Actuals Data. Estimates are stable post-Q1 raise with minimal revision activity, suggesting the street has largely digested the guidance update. The Yeztugo FY consensus sitting ~5% above management’s ~$1.0B target is the key watch item — if Q2 sequential growth slows materially, FY estimates could face downward pressure.

5. Stock Performance

Key Takeaway: GILD has underperformed XLV by ~15 percentage points since the Q1 print, with multiple compression (EV/EBITDA contracted from ~15x to ~14x) offsetting the underlying business beat — the market is discounting the IPR&D-driven EPS drag and waiting for sustained Yeztugo proof points.

GILD vs. XLV (Health Care Select Sector SPDR) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings (May 7, 2026). Source: Stock Price Data.

Since the Q1 2026 earnings close on May 7, 2026, GILD has declined approximately 2% (from $134.06 to ~$131), while XLV has rallied ~12% and the S&P 500 is roughly flat. The divergence is notable: GILD’s base business beat was overshadowed by the large acquired IPR&D charges that slashed reported EPS guidance, and the stock has not recovered. NTM EV/EBITDA has compressed from ~15x to ~14.3x over the period, suggesting the underperformance is multiple-driven rather than estimate-driven. The stock’s current setup — trading near the low end of its post-Q1 range — means a clean operational beat on Yeztugo and HIV could catalyze a re-rating, while any miss would likely accelerate the underperformance trend. Source: Stock Price Data.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the positive ISLEND-1/ISLEND-2 topline readout (June 8), which validates the ISL/LEN weekly oral HIV treatment franchise and expands Gilead’s long-acting HIV pipeline; the BIC/LEN PDUFA on August 27 is the next near-term binary catalyst.

• August 3, 2026 — California Supreme Court rules Gilead has no duty to develop safer HIV drug alternatives. In a 6-1 decision, the court reversed a 2024 appeals court ruling and established that drugmakers do not owe a duty to patients to develop safer alternatives to drugs already deemed safe. Removes a significant litigation tail risk for GILD’s HIV franchise, which accounts for ~70% of revenue. Shares were down 0.2% on the day, suggesting the market had largely priced in a favorable outcome.
• June 8, 2026 — ISLEND-1 and ISLEND-2 Phase 3 studies report positive topline results. Both studies met their primary efficacy endpoint at Week 48, demonstrating non-inferiority of islatravir/lenacapavir (ISL/LEN) once-weekly oral HIV treatment vs. Biktarvy and standard-of-care daily oral regimens. Gilead and Merck plan to file with regulatory authorities globally. Management framed the readout as enabling Gilead to capture switch patients currently going to non-Gilead regimens, targeting the ~20% of Biktarvy patients who seek to switch annually. Implication: Validates the long-acting oral HIV pipeline and extends the franchise runway well beyond Biktarvy’s 2036 LOE.
• June 4, 2026 — Ouro Medicines acquisition closed. Gilead and Galapagos (now Lakefront Biotherapeutics) equally split the $1.675B upfront payment plus up to $500M in milestones. Ouro’s lead asset gamgertamig (OM336) is a BCMA-CD3 T cell engager targeting autoimmune diseases, with registrational studies in select indications targeted as early as 2027. Implication: Completes the three-deal acquisition cycle; near-term M&A focus now shifts to integration.
• May 22, 2026 — Hepcludex (bulevirtide-gmod) receives FDA accelerated approval. Becomes the first and only approved treatment for chronic hepatitis delta virus (HDV) infection in the U.S., based on reductions in HDV RNA and ALT normalization from the Phase 3 MYR301 study. Implication: Adds a new commercial product to the liver disease franchise; confirmatory long-term outcomes study already initiated.
• May 21, 2026 — Tubulis acquisition closed. Adds TUB-040 (NaPi2b-directed Topo-I inhibitor ADC in Phase 1b/2 for platinum-resistant ovarian cancer and NSCLC) and TUB-030 (5T4 ADC), plus next-generation ADC platform technologies (P5 linker, AE5 payload). Implication: Strengthens Gilead’s oncology ADC capabilities alongside Trodelvy.
• May 7, 2026 — Q1 2026 earnings: beat-and-raise. Non-GAAP EPS beat; HIV sales +10% YoY; Yeztugo $166M (above expectations); Trodelvy +37% YoY; full-year product sales guidance raised $400M. Reported EPS guidance cut ~$9.50 due to $11.5B acquired IPR&D charges. Stock declined modestly on the day.
• May 7, 2026 — FDA accepts BIC/LEN NDA under priority review. PDUFA target action date: August 27, 2026. Phase 3 ARTISTRY-1 and ARTISTRY-2 data demonstrated comparable efficacy to complex regimens and Biktarvy at Week 48. Implication: BIC/LEN launch targeted for late August 2026 with modest 2026 revenues and a meaningful 2027 ramp; this is the single most important near-term binary catalyst for the stock.
• April 28, 2026 — Arcellx acquisition closed. $115/share plus $5 CVR; implied equity value ~$7.8B. Anito-cel BLA accepted by FDA with PDUFA December 23, 2026. Management targeting ~200 authorized treatment centers activated before year-end (described as 5x the number at which others have launched). Revenue expected to begin in early 2027. Implication: Full ownership enables faster execution; anito-cel positioned as the largest cell therapy launch by ATC count.

7. Insider Transaction Activity

Key Takeaway: All recent insider transactions are pre-planned 10b5-1 sales — no open-market discretionary buys or unusual sale clusters. The pattern is routine and does not signal concern or conviction.

Source: SEC Form 4 Filings Database; SEC Form 144 filing (O’Day, August 3, 2026). All transactions are under pre-established 10b5-1 trading plans. CEO O’Day sells 15,000 shares on the first of each month; CFO Dickinson sells 3,000 shares on the 15th of each month — both consistent with a systematic, obligation-driven plan. No open-market discretionary buys or unusual activity detected.

8. Peer Commentary: Current-Quarter & H2 2026 Read-Throughs

Key Takeaway: Peer Q2 2026 earnings calls (reported July 2026) provide several relevant signals for GILD’s Q2 and H2 2026 outlook: GSK’s HIV commentary is the most direct competitive read-through (Cabenuva share gains, Apretude vs. Yeztugo tolerability data); J&J’s Carvykti and bispecific growth confirm a robust cell therapy market but also intensifying competition; BMY’s Breyanzi seasonal moderation in Q3 is a direct read-through for GILD’s CAR-T products; and AbbVie’s payer access commentary is relevant for BIC/LEN’s Medicare formulary ramp.

Note on scope: Only commentary from Q2 2026 earnings calls (reported July–August 2026) that explicitly addresses Q3 2026 or H2 2026 outlook is included below. Prior-quarter results commentary and backward-looking statements are excluded.

GSK (Q2 2026 Earnings, July 28, 2026) — HIV: DIRECT Read-Through

Signal strength: HIGH — GSK competes directly with Gilead in both HIV treatment (Cabenuva vs. Biktarvy/BIC/LEN) and HIV prevention (Apretude vs. Yeztugo).

• Cabenuva gaining treatment share from competitors: GSK reported that 77% of new Cabenuva prescriptions in the U.S. came from competitor products, reflecting increasing confidence among HCPs and patients in long-acting treatment. This is a direct competitive signal for Gilead’s oral HIV treatment franchise (Biktarvy) and the upcoming BIC/LEN launch. Implication: The long-acting injectable treatment market is growing faster than the oral market, validating Gilead’s own long-acting strategy but also confirming that Cabenuva is actively converting Gilead patients.
• Apretude vs. Yeztugo tolerability data (Clarity study): GSK’s six-month follow-up Clarity study data showed 70% of participants rated Cabotegravir (Apretude) as “very or totally acceptable” vs. 37% for lenacapavir (Yeztugo), and 90% of participants continued to report lenacapavir-associated nodules at six months (20% severe). This is a direct competitive read-through for Yeztugo’s Q3 2026 persistency and market share trajectory. Implication: If the Clarity data gains traction with HCPs, it could pressure Yeztugo’s persistency advantage narrative — management’s claim that Yeztugo will have the “highest persistency in the HIV prevention category” faces a direct challenge.
• GSK raising HIV 2026 guidance to high-single-digit growth: GSK raised its 2026 HIV sales growth guidance to high-single-digit from mid-to-high-single-digit, driven by Cabenuva momentum. Implication: Confirms a healthy overall HIV market, but also signals that GSK is taking share in the long-acting segment that Gilead is targeting.
• Long-acting HIV market transformation: GSK characterized long-acting injectables as the “fastest growing segment” and stated it expects to launch its second and potentially third long-acting injectable treatment before any competitor enters the market, including a three-times-a-year prevention option targeted for 2027 approval. Implication: The competitive landscape for Yeztugo (Q6M) and the planned annual lenacapavir (Q12M, Purpose-365) will intensify in 2027–2028.
• PrEP market growing but Apretude holding share vs. Yeztugo: GSK noted that only 25% of people who could benefit from PrEP are currently taking it, confirming the large unmet need. GSK stated it is “holding share in a fast-growing market” against Yeztugo. Implication: Market growth is real and benefits both players, but Yeztugo is not taking share from Apretude as rapidly as some bulls had hoped.

Johnson & Johnson (Q2 2026 Earnings, July 15, 2026) — Cell Therapy & Oncology: DIRECT Read-Through

Signal strength: HIGH for cell therapy (Carvykti competes with Yescarta/Tecartus in hematologic oncology); MODERATE for oncology/ADC (competitive landscape context).

• Carvykti +47.7% growth in Q2 2026, driven by share gains and site expansion: J&J’s CAR-T for multiple myeloma grew 47.7% YoY, driven by share gains and continued authorized treatment center expansion. Implication: The cell therapy market for multiple myeloma is robust and growing, which is a positive read-through for anito-cel’s launch setup (PDUFA December 23, 2026). However, Carvykti’s strong growth also means the competitive bar for anito-cel is high.
• Tecvayli (bispecific) +56.1% growth, expanding into community settings: J&J’s BCMA x CD3 bispecific grew 56.1% with 25% QoQ increase in community site expansion. Management described it as “the first and only steroid-free, readily available immediate immunotherapy option” with “best-in-class efficacy and the potential for cure” in second-line multiple myeloma. Implication: Bispecifics are gaining traction in community settings — the same setting Gilead is targeting for anito-cel. This validates the community-setting opportunity but also confirms that bispecifics are a credible alternative to CAR-T in earlier lines.
• Tecvayli + Talvey data readout expected H2 2026 (1–4 prior lines): J&J expects data for Tecvayli in combination with Talvey for relapsed/refractory multiple myeloma patients with 1–4 prior lines of therapy in H2 2026. Implication: If positive, this combination could compete with anito-cel in earlier lines, potentially compressing the addressable market for anito-cel’s planned second-line expansion.
• Payer access: J-code drives 75% QoQ growth in new patient insertions for Lexo: J&J’s oncology product Lexo saw new patient insertions grow 75% QoQ after receiving a J-code, providing “a lot of confidence to providers in terms of reimbursement.” Implication: Reimbursement coding is a critical launch enabler — relevant for anito-cel’s commercial launch preparation.
• ACA subsidy expiration: no material impact observed: J&J stated it has not observed any meaningful impact on procedure volumes from ACA subsidy changes and does not expect a material impact on demand. Implication: Reduces the risk that ACA-related access changes will materially affect Gilead’s HIV or oncology patient volumes in Q3 2026.

Bristol Myers Squibb (Q2 2026 Earnings, July 30, 2026) — Cell Therapy & Pricing: DIRECT/INDIRECT Read-Through

Signal strength: HIGH for cell therapy seasonal dynamics (Breyanzi is a direct CAR-T comp); MODERATE for pricing/payer dynamics.

• Breyanzi +41% in Q2 2026, but Q3 seasonal moderation expected: BMY reported Breyanzi grew 41% in Q2 2026 driven by best-in-class profile and strong demand across approved indications in both U.S. and international markets. Critically, management guided that “typical summer demand patterns” will moderate Breyanzi growth in Q3 2026. Implication: This is a direct read-through for Gilead’s Yescarta and Tecartus in Q3 2026 — seasonal softness in cell therapy demand is a known pattern, and investors should expect Gilead’s CAR-T products to face similar headwinds in Q3.
• Iberdomide (cell modulator) launch readiness for August 17 PDUFA: BMY stated it is “awaiting the August 17th date for Iberdomide” and is ready for launch, describing it as “the first commercialized cell model” and a “brand new class of treatment for myeloma.” Management’s goal is to make Iberdomide and Mezigdomide “foundational in multiple myeloma, replacing rev and Pom in second line over time.” Implication: A new class of myeloma therapy launching in Q3 2026 adds competitive complexity to the multiple myeloma treatment landscape ahead of anito-cel’s December 2026 PDUFA.
• CPI penalty elimination benefits U.S. H2 2026 sales: BMY noted that “U.S. second half sales are expected to benefit from the elimination of the accumulated CPI penalty in certain government channels.” Implication: This is an indirect positive read-through for Gilead — if the same CPI penalty elimination applies to Gilead’s government channel products, it could provide a modest tailwind to HIV product revenues in H2 2026.

AbbVie (Q2 2026 Earnings, July 31, 2026) — Payer Access & Oncology: INDIRECT Read-Through

Signal strength: MODERATE — AbbVie’s payer access commentary is relevant for BIC/LEN’s Medicare formulary ramp; oncology ADC commentary provides competitive context for Trodelvy.

• Medicare formulary access for new launches will be delayed: AbbVie noted that for new product launches, “the ramp will be modest at first” because “we will not be immediately added into the Medicare formularies” — a process that “is going to take some more time based on the way those negotiations work.” Implication: This is a direct read-through for BIC/LEN’s launch trajectory. Even if BIC/LEN receives FDA approval on August 27, Medicare formulary inclusion will lag, meaning the 2026 revenue contribution will be modest and the 2027 ramp is the more meaningful event — consistent with management’s own guidance.
• Payer negotiations stable: low-single-digit rebate concessions remain the norm: AbbVie described payer contracting as “relatively consistent, very consistent with what we’ve seen over the years” with “low single digit concessions around rebates and price concessions as the standard.” Implication: No unusual pricing pressure in the current contracting season — a neutral read-through for Gilead’s HIV and oncology product pricing.
• ADC competition intensifying in solid tumors and hematology: AbbVie highlighted the launch of Technopaths (ADC for BPDCN), advancing Tmab-A in ovarian cancer and CRC, and a Phase 3 study in multiple myeloma including patients who “lost response to an anti-BCMA CAR-T or ADC.” Implication: The ADC competitive landscape is intensifying across Trodelvy’s key indications (TNBC, ovarian cancer) and in the post-CAR-T myeloma setting. This is a moderate negative read-through for Trodelvy’s longer-term competitive positioning.
• AbbVie myeloma Phase 3 interim analysis planned for Q3 2026: AbbVie noted a Phase 3 interim analysis is planned in Q3 2026 for progression-free survival from a monotherapy third-line-plus myeloma trial, with potential regulatory submission later in 2026 if positive. Implication: Additional myeloma data in Q3 2026 could shift the competitive narrative ahead of anito-cel’s December PDUFA.

Regeneron (Q2 2026 Earnings, July 30, 2026) — Oncology: INDIRECT Read-Through

Signal strength: LOW-MODERATE — Regeneron does not compete directly with Gilead in HIV or cell therapy; oncology commentary is general market context.

• Libtayo continued growth expected in H2 2026: Regeneron expects “continued growth for Libtayo in the second half of 2026” as it strives to gain incremental share in lung cancer and drive uptake across all approved stages of CSCC. Implication: Confirms a generally favorable oncology market environment for innovative therapies, which is a weak positive read-through for Trodelvy’s NSCLC and TNBC indications.
• Broad oncology pipeline commitment: Regeneron’s CSO emphasized the company will “continue to advance and take more shots in many different ways, both in monotherapies and combinations.” Implication: General market context; no specific read-through for Gilead.

Peer Read-Through Summary Table

Sources: GSK Q2 2026 Earnings Call Transcript (July 28, 2026); Johnson & Johnson Q2 2026 Earnings Call Transcript (July 15, 2026); Bristol Myers Squibb Q2 2026 Earnings Call Transcript (July 30, 2026); AbbVie Q2 2026 Earnings Call Transcript (July 31, 2026); Regeneron Q2 2026 Earnings Call Transcript (July 30, 2026). All commentary pertains to Q3 2026 or H2 2026 forward-looking statements made on these calls.